Cookson Peirce & Co. Inc. Takes Position in Krystal Biotech, Inc. $KRYS

Cookson Peirce & Co. Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,654 shares of the company’s stock, valued at approximately $998,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. grew its stake in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. AdvisorNet Financial Inc bought a new position in shares of Krystal Biotech in the 3rd quarter worth $30,000. Hantz Financial Services Inc. grew its position in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after purchasing an additional 179 shares during the period. Salomon & Ludwin LLC acquired a new stake in Krystal Biotech in the 3rd quarter valued at $33,000. Finally, First Horizon Advisors Inc. increased its stake in Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Up 2.3%

Krystal Biotech stock opened at $276.45 on Friday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $295.98. The company’s 50 day moving average price is $262.06 and its two-hundred day moving average price is $205.35. The stock has a market cap of $8.02 billion, a P/E ratio of 41.45 and a beta of 0.49.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 13.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on KRYS shares. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Bank of America upped their target price on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Chardan Capital lifted their price target on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.89.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.